3559 results for «358»

Filter By

3559 results

TAV-in-SAV - Part 1

08 Feb 2025 – From PCR Tokyo Valves 2025

Delve into the complex world of TAV-in-SAV (Transcatheter Aortic Valve-in-Surgical Aortic Valve) in this comprehensive session. Explore various case studies, including valve-in-valve TAVI in a patient with structural valve deterioration, a successful case of balloon-assisted BASILICA for TAV-in-TAV, and TAVI after valve sparing aortic replacement. Gain...

TAV-in-SAV - Part 1

Lifetime management - First valve choice matters

08 Feb 2025 – From PCR Tokyo Valves 2025

In this expert-led session, explore new frontiers in TAVI, focusing on bicuspid aortic valves, small annulus, and the risk of secondary interventions. Gain insights from the latest randomized trials (RHEIA) and registry data (CAvEAT), with real-world case discussions highlighting their clinical impact.

Lifetime management - First valve choice matters

TAVI complex cases: intravascular hemolysis, Heyde syndrome & more

08 Feb 2025 – From PCR Tokyo Valves 2025

This session presents a diverse array of complex TAVI cases, from interventions for paravalvular leak-induced intravascular hemolysis to cases of severe aortic tortuosity, calcification hindering valve expansion, and successful TAVI in patients with Heyde syndrome and HIV infection. Gain valuable insights into navigating these challenging scenarios.

TAVI complex cases: intravascular hemolysis, Heyde syndrome & more

Management of paravalvular leak

08 Feb 2025 – From PCR Tokyo Valves 2025

Explore this comprehensive session on the management of paravalvular leaks, a challenging complication following surgical or transcatheter valve replacements. Discover insights into managing post-operative pulmonary edema, percutaneous closure of left ventricular septal defects, and the nuances of mitigating recurrent paravalvular leaks. Dive into complex cases involving...

Management of paravalvular leak

Post-procedure complications: leaflet thrombus, hemolytic anemia & more

08 Feb 2025 – From PCR Tokyo Valves 2025

Explore this session to discover a range of post-procedure complications that can arise after TAVI, including subacute leaflet thrombus, hemolytic anemia after surgical aortic valve replacement, late migration of papillary fibroelastoma, sinus sequestration, delayed left main occlusion, and high-grade atrioventricular block. Additionally, learn about techniques to...

Post-procedure complications: leaflet thrombus, hemolytic anemia & more

TAVI and coronary artery disease

08 Feb 2025 – From PCR Tokyo Valves 2025

Delve into the complex interplay between TAVI and coronary artery disease in this comprehensive session. Explore the decision-making process for optimal sequencing of PCI and TAVI, and examine cases of acute myocardial infarction due to coronary embolism and delayed coronary obstruction following TAVI. Gain insights into...

TAVI and coronary artery disease

Redo mitral procedures

08 Feb 2025 – From PCR Tokyo Valves 2025

Explore this session to gain insights into the management of recurrent mitral regurgitation after percutaneous mitral valve interventions. Discover various redo procedures, including the use of the PASCAL system for recurrent MR after MitraClip, redo M-TEER for torn posterior leaflet, and successful redo TEER and MitraClip...

Redo mitral procedures

High-risk TAVI

08 Feb 2025 – From PCR Tokyo Valves 2025

Delve into the management of high-risk TAVI cases in this session. Discover innovative approaches, such as Impella-assisted TAVI in severe bicuspid aortic valve disease with severe left ventricular dysfunction, TAVR for pure native aortic regurgitation in surgically unfit patients, and the use of TAVI as a...

High-risk TAVI

TAV-in-TAV cases

08 Feb 2025 – From PCR Tokyo Valves 2025

Explore this session to delve into the complexities and challenges of TAV-in-TAV procedures. Gain insights into various case studies, including a successful TAV-in-TAV with coronary protection, a case of CABG and TAV-in-TAV, TAVI in a patient with failed homograft and three previous sternotomies, and concurrent mitral...

TAV-in-TAV cases

The value of WATCHMAN therapy - Who should we treat?

08 Feb 2025 – From PCR Tokyo Valves 2025

Delve into the value of WATCHMAN therapy in this sponsored session by Boston Scientific. Explore the latest evidence and future perspectives of this innovative treatment option. Understand who the ideal patient is for WATCHMAN therapy and how to identify them in daily clinical practice, including TAVI...

The value of WATCHMAN therapy - Who should we treat?

Standardised implant technique with self-expandable valve

08 Feb 2025 – From PCR Tokyo Valves 2025

Don’t miss this PCR Tokyo Valves 2025 session replay, where leading experts share key techniques for simplifying and optimising TAVI procedures with the Evolut device. This session covers essential insights into safely performing procedures on patients with various anatomical types using the self-expandable valve, while emphasising...

Standardised implant technique with self-expandable valve

Mitral valve-in-valve and valve-in-ring electrosurgery

08 Feb 2025 – From PCR Tokyo Valves 2025

Mitral valve-in-valve and valve-in-ring electrosurgery

Coronary complications: sharing the unusual ones

23 May 2025 – From EuroPCR 2025

This session shares unusual coronary complications including microcatheter tip entrapment, balloon shaft fracture, coronary balloon rupture salvage, and retained equipment retrieval, highlighting innovative solutions and procedural vigilance.

Coronary complications: sharing the unusual ones

SURTAVI: five-year results from a randomized trial of TAVR vs. SAVR in patients at intermediate surgical risk

07 Nov 2021

Although TAVI is an accepted alternative to surgery in patients with severe aortic stenosis who are at high surgical risk, less is known about long-term comparative outcomes among patients with aortic stenosis who are at intermediate surgical risk. P. Redaelli & M. Pighi review the SURTAVI trial...

Paola Redaelli

Author

Paola Redaelli
M. Pighi

Author

Michele Pighi
SURTAVI: five-year results from a randomized trial of TAVR vs. SAVR in patients at intermediate surgical risk

World Heart Day 2023: Reducing the burden of cardiovascular disease globally: beyond stents and balloons!

29 Sep 2023

Global burden of Cardiovascular Disease

Cardiovascular disease (CVD) remains the lead cause of mortality for men and women globally. Our world population in 2023 is 8 billion! Of these, around 620 million people are living with heart and circulatory diseases across the world. Each year around 60...

Vijay Kunadian

Author

Vijay Kunadian
World Heart Day 2023

OPTIMIZE IDE: A randomized trial of a novel, ultra low profile fixed-wire DES

26 Oct 2020

At TCT Connect 2020, Late-Breaking Trial Session IV, the primary results of the OPTIMIZE IDE were presented by Dean J. Kereiakes. Daniele Giacoppo provides a summary of the trial.

Daniele Giacoppo

Author

Daniele Giacoppo
Live from TCT Connect 2020: The OPTIMIZE trial

The Lancet Commission to reduce global burden of cardiovascular disease in women by 2030

29 Aug 2021

Vijay Kunadian summarizes the key points of the LBT session of the ESC congress 2021 held on Sunday, 29 August focusing on the Lancet Commission to reduce the global burden of heart disease in women by 2030.

Vijay Kunadian

Author

Vijay Kunadian
ESC Congress 2021 - Global burden of cardiovascular disease in women; 20/20 vision for 2030: report of The Lancet commission

BRIGHT-4 – Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial

07 Nov 2022

Nicola Ryan provides her take on the BRIGHT-4 study, which was presented during AHA 2022 in Chicago, & simultaneously published in the Lancet.

This study was a randomised control trial designed to assess if bivalirudin plus a high dose infusion for 2-4 hours post PPCI was superior to unfractionated...

Nicola Ryan

Author

Nicola Ryan
BRIGHT-4 – Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial

Drug-coated balloon (DCB) technology: A pioneer’s view of the historical evolution and future directions

08 Jan 2025

In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.

Author

Bruno Scheller
Drug-coated balloon (DCB) technology: A pioneer’s view of the historical evolution and future directions
Didn’t find what you were looking for?